Biomarkers in Early Detection, Prognostication and Management of Gastrointestinal Tract Malignancies: A Review

Abstract

Each year the risk of cancer cases is constantly on the rise. The reoccurrence of this dilemma is due to late diagnosis, and as a result the survival rate is low. This indicates the significance of creating more efficient instruments for timely detection of cancerous cells, assessment, as well as prognosis. Hence, the objective of this paper was to provide a critical review of biomarkers in early detection, prognostication and management of gastrointestinal tract malignancies by harvesting data from online sources and libraries. Data obtained reveals that gastrointestinal tracts (GI) malignancies, encompasses malignancies that may arise from the gastric, hepatic, colonic, esophagus, gallbladder, rectal and stomach tumors are a common kind of cancer and could affect 1.400,000 - 952,000,000 people worldwide. A potential method for improving the diagnosis as well as prognosis of GI malignancy is the use of biomarkers, which are quantifiable indicators of biological processes or state of the ailments. Significant development has been made recently in detecting and validating biomarkers for various clinical procedures. This review discuss the present situation of gastrointestinal cancer biomarker research, with an emphasis on moral issues and other clinical implications that may arise from the incorporation of biomarkers in clinical practices, and also the different category of biomarkers, including genetic, epigenetic, and protein-based markers, are examined, along with their contributions to future outcomes in the management of gastrointestinal malignancies.